- |||||||||| Ravicti (glycerol phenylbutyrate) / Immedica, Amgen
Enrollment open: Use of Ravicti (clinicaltrials.gov) - Sep 23, 2013 P2, N=6, Recruiting, Not yet recruiting --> Recruiting
- |||||||||| Neupogen (filgrastim) / Kyowa Kirin, Amgen, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment closed: Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells (clinicaltrials.gov) - Sep 23, 2013 P2, N=20, Active, not recruiting, Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||||||||| litronesib (KF 89617) / Kyowa Kirin, Eli Lilly
Trial completion, Metastases: A Study of LY2523355 in Participants With Breast Cancer (clinicaltrials.gov) - Sep 22, 2013 P2, N=60, Completed, Completed --> Terminated; Due to poor accrual Active, not recruiting --> Completed
- |||||||||| Avastin (bevacizumab) / Roche, dulanermin (AMG 951) / Amgen, Roche
Trial completion, Combination therapy, Metastases: A Study of Dulanermin Administered in Combination With Camptosar (clinicaltrials.gov) - Sep 8, 2013 P1, N=42, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| pazopanib / Generic mfg.
Enrollment change, Metastases: Pazopanib, Docetaxel, Prednisone Prostate (clinicaltrials.gov) - Sep 2, 2013 P1, N=36, Recruiting, Active, not recruiting --> Completed N=122 --> 36
- |||||||||| prezalumab (AMG 557) / Amgen, AstraZeneca
Trial initiation date: Safety Study of AMG 557 in Subjects With Lupus Arthritis (clinicaltrials.gov) - Aug 29, 2013 P1, N=40, Recruiting, Recruiting --> Terminated; Material sponsor withdrew support Initiation date: Jan 2012 --> Jun 2012
|